Akers Biosciences Announces a Change to the Board of Directors

THOROFARE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces that Raymond F. Akers Jr., Ph.D has resigned as a director of the Company with immediate effect.

Pursuant to U.S. Federal Securities Laws, within four business days the Company will file a Form 8-K with the Securities and Exchange Commission, which may include further information with respect to the resignation.

For more information:

Akers Biosciences, Inc.John J. Gormally, Chief Executive OfficerTel. +1 856 848 8698

Vigo Communications (Global Public Relations)Ben Simons / Fiona HensonTel. +44 (0)20 7830 9704Email: [email protected]

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. The forward-looking statements include statements or expectations regarding the effects on the Company due to the resignation of Raymond F. Akers Jr., Ph.D from the Board of  the Company, other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission and other future events. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Source: Akers Biosciences Inc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bitdeer acquires 200 acres in Texas for $100M to expand AI/HPC
• Shell completes $16.5B acquisition of ARC Resources
• Ming Shing closes $510M acquisition of Meals Through Seasons Limited